Tvardi Therapeutics (0HTC) Stock Overview

A clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. More details

0HTC fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Earnings are forecast to decline by an average of 16.9% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($17M)

+ 1 more risk

0HTC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW485,434 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

485,434 investors already sharing narratives

View all narratives

Tvardi Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tvardi Therapeutics
Historical stock prices
Current Share Price	US$3.38
52 Week High	US$3.38
52 Week Low	US$3.38
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	0HTC	GB Pharmaceuticals	GB Market
7D	0%	0.6%	0.01%
1Y	n/a	11.9%	18.5%

Return vs Industry: Insufficient data to determine how 0HTC performed against the UK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 0HTC performed against the UK Market.

Price Volatility

Is 0HTC's price volatile compared to industry and market?
0HTC volatility
0HTC Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	5.1%
10% most volatile stocks in GB Market	10.4%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0HTC's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0HTC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	12	Imran Alibhai	tvarditherapeutics.com

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Tvardi Therapeutics, Inc. Fundamentals Summary

How do Tvardi Therapeutics's earnings and revenue compare to its market cap?
0HTC fundamental statistics
Market cap	US$16.51m
Earnings (TTM)	-US$15.44m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.1x

P/E Ratio

Is 0HTC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HTC income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$15.44m
Earnings	-US$15.44m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.65
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 0HTC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/11 12:11
End of Day Share Price	2026/07/13 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tvardi Therapeutics, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Etzer Darout	Barclays
Julian Harrison	BTIG
Steven Seedhouse	Cantor Fitzgerald & Co.

Tvardi Therapeutics, Inc.LSE:0HTC Stock Report